Revelation Biosciences Reports Third Quarter 2026 Financial Results, Highlights Gemini Development and $94 Billion Market Opportunity
Revelation Biosciences, Inc., a clinical-stage life sciences company focused on developing innovative therapeutic solutions for acute and chronic diseases, has announced its financial results for the third quarter and nine months ended September 30, 2026. Alongside its financial performance, the company provided updates on its corporate activities, highlighting progress in the development of its investigational product candidate Gemini and preparations for an upcoming clinical study evaluating the treatment in patients with acute kidney injury (AKI).
During the reporting period, Revelation continued advancing its clinical and commercial development strategy, with particular attention to assessing the market opportunity for Gemini and establishing the operational infrastructure required to support future clinical research. The company’s recent activities include the release of an independent market assessment estimating a potential total addressable market of approximately $94 billion for Gemini and the selection of a full-service contract research organization (CRO) with global operational capabilities for its planned Phase 2/3 TITAN study.
These developments represent important steps in Revelation’s efforts to advance Gemini through clinical development while evaluating its potential commercial opportunities across relevant disease areas.
The company also reported its financial position as of September 30, 2026, including cash and cash equivalents of $9.1 million. Based on its current operating plans and financial projections, Revelation expects its available cash resources to fund operations into the second quarter of 2027.
James Rolke, Chief Executive Officer of Revelation Biosciences, emphasized the company’s continued commitment to advancing Gemini and developing potential treatment options that could benefit patients.
“The Revelation team remains focused on progressing Gemini’s development for the benefit of patients,” said Rolke. He added that the company looks forward to providing additional updates in the near term as its development activities continue.
Revelation Biosciences Advances Gemini Development Strategy
Gemini remains a central component of Revelation’s development strategy as the company works to evaluate its potential applications in acute and chronic diseases.
As a clinical-stage life sciences company, Revelation is focused on developing innovative therapeutic approaches intended to address medical conditions where additional treatment options may be needed. Its development activities are directed toward advancing its investigational programs through clinical research and generating evidence to support their potential therapeutic value.
The company’s latest corporate update demonstrates its intention to progress Gemini through the next stages of development while strengthening the clinical and operational capabilities needed to support its research objectives.
One of the major developments reported during the third quarter period was the completion and release of an independent market assessment examining Gemini’s potential commercial opportunity. According to the assessment, the product candidate could address a total potential market opportunity of approximately $94 billion.
This estimated market size provides an indication of the potential commercial opportunity associated with Gemini, subject to the successful completion of clinical development, regulatory approvals and eventual commercialization.
Market assessments are an important component of biotechnology development because they help companies evaluate the potential demand for investigational treatments, identify relevant patient populations and understand the commercial landscape in which a product could eventually compete.
For Revelation, the assessment provides additional information to support its longer-term development strategy. The estimated $94 billion total addressable market highlights the potential scale of the opportunity that the company is evaluating for Gemini.
However, the commercial potential of any investigational therapeutic remains dependent on several factors, including clinical efficacy, safety, regulatory requirements, market access, reimbursement considerations and competition from existing and emerging treatment options.
The company is therefore continuing to prioritize clinical development and the generation of supporting data as it works toward establishing the potential role of Gemini in patient care.
Company Selects Global CRO for Phase 2/3 TITAN Study in Acute Kidney Injury
Another important corporate development involved Revelation’s selection of a full-service contract research organization to support its upcoming clinical study evaluating Gemini in patients with acute kidney injury.
The company selected Avance Clinical as its CRO for the planned Phase 2/3 TITAN study.
The selection of a CRO represents an important operational milestone as Revelation prepares to advance its clinical research program. Contract research organizations provide specialized services that help biotechnology and pharmaceutical companies plan, coordinate and conduct clinical trials.
Depending on the scope of a clinical program, CRO responsibilities can include clinical trial management, study monitoring, regulatory support, site coordination, data management and other operational activities necessary to conduct research in accordance with applicable clinical and regulatory requirements.
By selecting a full-service CRO with global operations, Revelation aims to establish the infrastructure needed to support its upcoming study and facilitate the execution of its clinical development plans.
The TITAN study is intended to evaluate Gemini in patients with acute kidney injury, a serious medical condition characterized by a sudden decline in kidney function.
Acute kidney injury can develop over a relatively short period and may occur in association with severe illness, hospitalization, major surgery, infections or other underlying medical complications. The condition can interfere with the kidneys’ ability to remove waste products and maintain fluid and electrolyte balance.
AKI represents an important area of clinical research because it can be associated with significant complications, prolonged hospital stays and an increased risk of adverse health outcomes. Patients experiencing acute kidney injury may require close medical monitoring and supportive treatment, depending on the severity and underlying cause of the condition.
The selection of Avance Clinical is expected to support Revelation’s efforts to prepare for and conduct the planned Phase 2/3 TITAN study.
For a clinical-stage company, choosing an experienced CRO can be an important part of managing the complexity of clinical development. Clinical trials require coordination among investigators, participating research sites, regulatory stakeholders and other service providers.
A full-service organization with global capabilities can help provide the operational resources required to manage these activities and support the company’s clinical development objectives.
Although Revelation has announced the CRO selection, the company has not provided additional study-specific details in the financial update, such as the planned enrollment target, participating countries, trial duration or anticipated data readout.
The upcoming TITAN study is nevertheless an important component of the company’s efforts to advance Gemini in acute kidney injury and generate clinical evidence that could inform its future development.
Independent Market Assessment Identifies Potential $94 Billion Opportunity
Revelation’s independent market assessment represents another significant element of its corporate progress during the reporting period.
The assessment identified a potential total addressable market of approximately $94 billion for Gemini, highlighting the potential commercial scale that the company is evaluating for its investigational product candidate.
Total addressable market estimates are commonly used by biotechnology companies and investors to understand the potential revenue opportunity associated with a product or therapeutic category.
Such assessments generally consider factors such as the size of relevant patient populations, disease prevalence, treatment patterns, potential demand and the broader healthcare market.
For Revelation, the findings provide a framework for understanding Gemini’s potential market opportunity as the company continues its clinical development activities.
The estimated market opportunity may also help inform longer-term strategic planning, including potential commercialization approaches and future business development considerations.
Nevertheless, an estimated addressable market should not be interpreted as projected revenue or an indication of guaranteed commercial success. The ability to capture any portion of the estimated market will depend on Gemini’s clinical performance, regulatory pathway, pricing, reimbursement, competitive environment and adoption by healthcare providers.
The company will need to demonstrate that Gemini offers meaningful clinical benefits and satisfies the relevant regulatory requirements before it can become an approved treatment option.
Revelation’s continued focus on clinical development alongside its market assessment reflects an approach that combines scientific progress with an evaluation of potential commercial opportunities.
Financial Results for the Third Quarter Ended September 30, 2026
Revelation reported cash and cash equivalents of $9.1 million as of September 30, 2026, compared with $10.7 million as of December 31, 2025.
The decrease of approximately $1.6 million reflected the company’s cash utilization during the reporting period. According to Revelation, the change was primarily attributable to net cash proceeds received through the January 2026 warrant inducement, offset by cash used in operating activities.
The company’s available cash resources remain an important consideration as it continues investing in research and development, clinical preparation and corporate operations.
Based on its current operating plans and projections, management believes that the company’s cash and cash equivalents will be sufficient to support operations into the second quarter of 2027.
This financial outlook provides an indication of the expected funding runway under the company’s current assumptions. Actual cash requirements may change depending on clinical development expenses, operational costs, financing activities and other business needs.
For clinical-stage biotechnology companies, maintaining sufficient financial resources is particularly important because clinical studies can require substantial investments over extended periods.
Revelation’s ability to manage its available capital while progressing Gemini through development will therefore remain an important factor in determining the pace of its future activities.
Third-quarter operating cash flow and net loss
For the three months ended September 30, 2026, Revelation reported net cash used in operating activities of $2.6 million, compared with $1.6 million for the corresponding period in 2025.
The increase in operating cash utilization reflects the company’s spending during the quarter as it continued supporting its business and development activities.
Net loss for the third quarter of 2026 was $3.3 million, equivalent to a basic and diluted net loss of $5.92 per share.
For the same three-month period in 2025, the company reported a net loss of $1.9 million, representing a basic and diluted net loss of $49.51 per share.
The year-over-year increase in the reported quarterly net loss highlights the financial costs associated with maintaining operations and supporting the company’s development strategy.
However, per-share comparisons should also be considered in the context of changes in the company’s weighted-average shares outstanding, as these can significantly influence reported earnings or losses per share.
Nine-month financial performance
For the nine months ended September 30, 2026, Revelation reported a net loss of $9.6 million, compared with a net loss of $6.4 million for the corresponding nine-month period in 2025.
The company’s basic and diluted net loss per share for the first nine months of 2026 was $29.37, compared with $273.33 for the same period in the previous year.
These results reflect the company’s financial performance during the first three quarters of 2026 as it continued pursuing its corporate and clinical development objectives.
The increase in the cumulative net loss indicates higher overall losses compared with the corresponding period in 2025. As with the quarterly results, per-share figures are influenced by the number of shares outstanding during the respective reporting periods.
For investors evaluating Revelation’s financial position, the company’s cash balance, operating cash utilization and expected funding runway will be important indicators to monitor alongside progress in its clinical development programs.
Financial Position and Expected Cash Runway Into Q2 2027
The company’s reported cash position of $9.1 million at September 30, 2026, provides the financial foundation for its ongoing operations and planned development activities.
Management expects the available cash and cash equivalents to support operations into the second quarter of 2027, based on current operating plans and financial projections.
This anticipated runway is particularly relevant as Revelation prepares for the planned Phase 2/3 TITAN study.
Clinical development programs generally involve multiple stages of planning and execution, including CRO engagement, site preparation, regulatory coordination, patient recruitment, study monitoring and data collection.
These activities can create additional financial requirements as a clinical-stage company moves from development planning toward the execution of a larger clinical study.
Revelation’s selection of Avance Clinical and its ongoing focus on Gemini demonstrate that the company is continuing to advance its development strategy while managing its available financial resources.
The expected funding runway into the second quarter of 2027 provides a planning horizon for these activities. However, it does not eliminate the possibility that additional financing could be required in the future, particularly if clinical development costs increase or the company expands its research activities.
The company will need to balance its operational spending with its objective of achieving meaningful clinical progress.
Management Reaffirms Commitment to Advancing Gemini
Commenting on the company’s progress, CEO James Rolke reiterated Revelation’s commitment to advancing Gemini for the benefit of patients.
His remarks highlighted the importance of continuing development activities and maintaining momentum as the company works toward its next milestones.
The company’s recent achievements, including the independent market assessment and CRO selection, demonstrate progress across both commercial evaluation and clinical development preparation.
The planned TITAN study is expected to be an important next step in evaluating Gemini in acute kidney injury. The selection of a global CRO provides Revelation with an external clinical research partner to support the study’s execution.
At the same time, the independent market assessment provides insight into the potential commercial opportunity associated with Gemini, although clinical and regulatory success will remain essential before any market opportunity can be realized.
Revelation indicated that it expects to provide further updates in the near term, suggesting that additional information about its development activities and corporate progress may be communicated as the program advances.
Revelation Biosciences’ third-quarter 2026 financial update reflects the company’s continued focus on advancing Gemini while managing its financial resources and preparing for future clinical research.
The identification of a potential $94 billion total addressable market provides an important commercial perspective on Gemini’s potential opportunity. Meanwhile, the selection of Avance Clinical as the CRO for the planned Phase 2/3 TITAN study represents an operational step toward evaluating the investigational treatment in patients with acute kidney injury.
Financially, the company reported $9.1 million in cash and cash equivalents as of September 30, 2026, and expects its available resources to fund operations into the second quarter of 2027 under its current plans and projections.
Going forward, important areas to monitor will include preparations for the TITAN study, the progression of Gemini’s clinical development, additional information regarding its therapeutic potential and the company’s ability to manage its operating expenses.
As a clinical-stage life sciences company, Revelation’s future progress will depend significantly on its ability to generate meaningful clinical evidence, maintain adequate financial resources and advance its investigational programs through the development process.
Through its continued focus on Gemini, clinical research preparation and strategic market evaluation, Revelation Biosciences aims to advance potential therapeutic solutions for patients with acute and chronic diseases while building a foundation for its longer-term growth.
About Gemini
Gemini is the Company’s proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD®), a toll-like receptor 4 (TLR4) agonist. TLR4 stimulation with Gemini rebalances the innate immune response and has been demonstrated to have the potential to treat acute and chronic diseases associated with dysregulated inflammation.
Gemini is currently being evaluated as a potential treatment for acute kidney injury (GEM-AKI); Gemini is also being developed as a treatment for chronic kidney disease (GEM-CKD), as a treatment to reduce hyperinflammation and infection associated with severe burn (GEM-PBI), and as a treatment to prevent post-surgical infection (GEM-PSI). The potential of Gemini to correct dysregulated inflammation has been demonstrated in multiple preclinical models of AKI, CKD, and infection, as well as in two Phase 1 clinical studies. See additional details here.
About Revelation Biosciences, Inc.
Revelation Biosciences, Inc. is a clinical-stage life sciences company focused on rebalancing inflammation using its proprietary formulation, Gemini. Revelation has multiple ongoing programs to evaluate Gemini as a treatment for acute kidney injury, a treatment for chronic kidney disease, prevention of post-surgical infection, and a treatment to reduce hyperinflammation and infection associated with severe burn.